Komori
Noevir Holdings (4928) · InitiativeDropped

Efficient management of selling, general and administrative expenses in the pharmaceuticals and food businesses

First written in FY2018. 3 of 5 entries say "Restated". Latest entry: FY2020.

5entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018 – FY20202018: 12019: 320192020: 12020
Same theme, other companies
Improved profitability through greater SG&A efficiency in the pharmaceuticals and food businessA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2020DroppedAnnual report

    「Revenue from the pharmaceuticals and food businesses was ¥11,273 million, down 6.3% year on year, and segment profit was ¥1,261 million, down 3.8%.」

    Efficient management of selling, general and administrative expenses, which had been cited as a factor contributing to higher profit through the previous quarter, is not explicitly mentioned in the full-year performance explanation.
  2. FY2019-Q3RestatedAnnual report

    「The pharmaceuticals and food business reported net sales of ¥8,982 million, down 4.1% year on year, and segment profit of ¥1,054 million, up 28.7%. Profit increased due in part to more efficient management of selling, general and administrative expenses.」

    Despite declining revenue in the pharmaceuticals and food businesses, the explanation that efficient management of selling, general and administrative expenses, among other factors, contributed to higher profit continues.
  3. FY2019-Q2RestatedAnnual report

    「Profit increased due in part to the efficient management of selling, general and administrative expenses.」

    Despite declining revenue in the pharmaceuticals and food businesses, the explanation that efficient management of selling, general and administrative expenses contributed to higher profit continues.
  4. FY2019-Q1RestatedAnnual report

    「Profit increased due in part to the efficient management of selling, general and administrative expenses.」

    Despite declining revenue in the pharmaceuticals and food businesses, the explanation that efficient management of selling, general and administrative expenses contributed to higher profit continues.
  5. FY2018First statedAnnual report

    「Profit increased due in part to the efficient management of selling, general and administrative expenses.」

    Despite declining revenue in the pharmaceuticals and food businesses, efficient management of selling, general and administrative expenses is explained specifically for the first time as a factor contributing to higher profit.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Noevir Holdings's next results are scheduled for 2026-11-10. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.